SK13652003A3 - Potenciácia terapeutického účinku mastných kyselín - Google Patents

Potenciácia terapeutického účinku mastných kyselín Download PDF

Info

Publication number: SK13652003A3
Authority: SK; Slovakia
Prior art keywords: disease; acid; cox; disorder; pharmaceutical composition
Prior art date: 2001-05-09

Application number

SK1365-2003A

Other languages

English (en)

Slovak (sk)

Inventor

David Frederick Horrobin

Original Assignee

Laxdale Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-09

Filing date

2002-05-09

Publication date

2004-07-07

2002-05-09 Application filed by Laxdale Limited filed Critical Laxdale Limited

2004-07-07 Publication of SK13652003A3 publication Critical patent/SK13652003A3/sk

Links

235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 55
229930195729 fatty acid Natural products 0.000 title claims abstract description 55
239000000194 fatty acid Substances 0.000 title claims abstract description 55
150000004665 fatty acids Chemical class 0.000 title claims abstract description 53
230000001225 therapeutic effect Effects 0.000 title abstract description 11
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 28
235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 28
229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 26
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 26
102000004190 Enzymes Human genes 0.000 claims abstract description 21
108090000790 Enzymes Proteins 0.000 claims abstract description 21
239000003112 inhibitor Substances 0.000 claims abstract description 21
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims abstract description 20
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims abstract description 20
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 18
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims abstract description 18
101710159002 L-lactate oxidase Proteins 0.000 claims abstract 6
102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims abstract 6
101710153103 Long-chain-fatty-acid-CoA ligase FadD13 Proteins 0.000 claims abstract 4
101710153099 Long-chain-fatty-acid-CoA ligase FadD15 Proteins 0.000 claims abstract 4
101710154693 Medium/long-chain-fatty-acid-CoA ligase FadD17 Proteins 0.000 claims abstract 4
101710141422 Medium/long-chain-fatty-acid-CoA/3-oxocholest-4-en-26-oate-CoA ligase Proteins 0.000 claims abstract 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 32
239000003814 drug Substances 0.000 claims description 30
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
239000000203 mixture Substances 0.000 claims description 28
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 25
201000010099 disease Diseases 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 18
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 16
235000021342 arachidonic acid Nutrition 0.000 claims description 16
229940114079 arachidonic acid Drugs 0.000 claims description 16
239000002532 enzyme inhibitor Substances 0.000 claims description 16
206010028980 Neoplasm Diseases 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 14
229940111134 coxibs Drugs 0.000 claims description 13
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 13
208000027866 inflammatory disease Diseases 0.000 claims description 13
235000020669 docosahexaenoic acid Nutrition 0.000 claims description 12
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 12
235000020778 linoleic acid Nutrition 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 12
HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 11
235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims description 11
OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 11
HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 11
JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 11
229940090949 docosahexaenoic acid Drugs 0.000 claims description 9
208000020016 psychiatric disease Diseases 0.000 claims description 9
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 8
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 8
210000003734 kidney Anatomy 0.000 claims description 8
206010007027 Calculus urinary Diseases 0.000 claims description 7
201000004624 Dermatitis Diseases 0.000 claims description 7
208000006673 asthma Diseases 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
229940125532 enzyme inhibitor Drugs 0.000 claims description 7
210000004994 reproductive system Anatomy 0.000 claims description 7
208000030159 metabolic disease Diseases 0.000 claims description 6
230000000926 neurological effect Effects 0.000 claims description 6
150000003904 phospholipids Chemical class 0.000 claims description 6
208000023504 respiratory system disease Diseases 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 5
206010012289 Dementia Diseases 0.000 claims description 5
208000023105 Huntington disease Diseases 0.000 claims description 5
208000001132 Osteoporosis Diseases 0.000 claims description 5
208000012931 Urologic disease Diseases 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 5
210000004556 brain Anatomy 0.000 claims description 5
208000026106 cerebrovascular disease Diseases 0.000 claims description 5
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
208000016097 disease of metabolism Diseases 0.000 claims description 5
230000002526 effect on cardiovascular system Effects 0.000 claims description 5
208000017169 kidney disease Diseases 0.000 claims description 5
230000027758 ovulation cycle Effects 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
208000014001 urinary system disease Diseases 0.000 claims description 5
208000008281 urolithiasis Diseases 0.000 claims description 5
208000007848 Alcoholism Diseases 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 4
208000020925 Bipolar disease Diseases 0.000 claims description 4
206010009900 Colitis ulcerative Diseases 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 4
206010026749 Mania Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
208000028017 Psychotic disease Diseases 0.000 claims description 4
201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
201000007930 alcohol dependence Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
208000010668 atopic eczema Diseases 0.000 claims description 4
208000030963 borderline personality disease Diseases 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
206010015037 epilepsy Diseases 0.000 claims description 4
125000004494 ethyl ester group Chemical group 0.000 claims description 4
210000001508 eye Anatomy 0.000 claims description 4
206010016256 fatigue Diseases 0.000 claims description 4
210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
208000013403 hyperactivity Diseases 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
208000022821 personality disease Diseases 0.000 claims description 4
201000000980 schizophrenia Diseases 0.000 claims description 4
206010006298 Breast pain Diseases 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
208000005171 Dysmenorrhea Diseases 0.000 claims description 3
206010013935 Dysmenorrhoea Diseases 0.000 claims description 3
201000009273 Endometriosis Diseases 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
208000006662 Mastodynia Diseases 0.000 claims description 3
208000012902 Nervous system disease Diseases 0.000 claims description 3
208000025966 Neurological disease Diseases 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
208000026723 Urinary tract disease Diseases 0.000 claims description 3
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
208000022458 calcium metabolism disease Diseases 0.000 claims description 3
150000001840 cholesterol esters Chemical class 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
238000009472 formulation Methods 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
208000015122 neurodegenerative disease Diseases 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
206010061216 Infarction Diseases 0.000 claims description 2
206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
208000009911 Urinary Calculi Diseases 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
210000004369 blood Anatomy 0.000 claims description 2
239000008280 blood Substances 0.000 claims description 2
229910003002 lithium salt Inorganic materials 0.000 claims description 2
159000000002 lithium salts Chemical class 0.000 claims description 2
208000017520 skin disease Diseases 0.000 claims description 2
208000015202 calcium metabolic disease Diseases 0.000 claims 2
229940098330 gamma linoleic acid Drugs 0.000 claims 2
208000022610 schizoaffective disease Diseases 0.000 claims 2
239000004575 stone Substances 0.000 claims 2
210000001635 urinary tract Anatomy 0.000 claims 2
238000011260 co-administration Methods 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
201000010901 lateral sclerosis Diseases 0.000 claims 1
208000005264 motor neuron disease Diseases 0.000 claims 1
235000004626 essential fatty acids Nutrition 0.000 abstract description 43
102000003820 Lipoxygenases Human genes 0.000 description 24
108090000128 Lipoxygenases Proteins 0.000 description 24
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 20
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 20
229940079593 drug Drugs 0.000 description 19
230000000694 effects Effects 0.000 description 13
150000001875 compounds Chemical class 0.000 description 10
235000020664 gamma-linolenic acid Nutrition 0.000 description 9
210000004027 cell Anatomy 0.000 description 7
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
229960000590 celecoxib Drugs 0.000 description 6
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 6
229960002733 gamolenic acid Drugs 0.000 description 6
229960001680 ibuprofen Drugs 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
150000002066 eicosanoids Chemical class 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
150000003180 prostaglandins Chemical class 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
-1 Prostaglandins Leukotrienes Chemical class 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000005516 coenzyme A Substances 0.000 description 4
229940093530 coenzyme a Drugs 0.000 description 4
235000021588 free fatty acids Nutrition 0.000 description 4
229960000905 indomethacin Drugs 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 3
235000020661 alpha-linolenic acid Nutrition 0.000 description 3
229940124599 anti-inflammatory drug Drugs 0.000 description 3
229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 3
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
229940094443 oxytocics prostaglandins Drugs 0.000 description 3
239000000758 substrate Substances 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
102000005870 Coenzyme A Ligases Human genes 0.000 description 2
235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000015439 Phospholipases Human genes 0.000 description 2
108010064785 Phospholipases Proteins 0.000 description 2
102000006447 Phospholipases A2 Human genes 0.000 description 2
108010058864 Phospholipases A2 Proteins 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
238000010306 acid treatment Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
229960000371 rofecoxib Drugs 0.000 description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
235000021122 unsaturated fatty acids Nutrition 0.000 description 2
150000004670 unsaturated fatty acids Chemical class 0.000 description 2
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
235000016425 Arthrospira platensis Nutrition 0.000 description 1
240000002900 Arthrospira platensis Species 0.000 description 1
102000014461 Ataxins Human genes 0.000 description 1
108010078286 Ataxins Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
206010008025 Cerebellar ataxia Diseases 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
208000024412 Friedreich ataxia Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
206010068871 Myotonic dystrophy Diseases 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
PDODBKYPSUYQGT-UHFFFAOYSA-N acetic acid;1h-indene Chemical class CC(O)=O.C1=CC=C2CC=CC2=C1 PDODBKYPSUYQGT-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002905 effect on arthritis Effects 0.000 description 1
SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
229960004945 etoricoxib Drugs 0.000 description 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
229960002600 icosapent ethyl Drugs 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960000965 nimesulide Drugs 0.000 description 1
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229960004662 parecoxib Drugs 0.000 description 1
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
208000017443 reproductive system disease Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
150000003872 salicylic acid derivatives Chemical class 0.000 description 1
230000011664 signaling Effects 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
229940082787 spirulina Drugs 0.000 description 1
238000011255 standard chemotherapy Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
125000005457 triglyceride group Chemical group 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229960002004 valdecoxib Drugs 0.000 description 1
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Obesity (AREA)
Dermatology (AREA)
Addiction (AREA)
Psychology (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Emergency Medicine (AREA)

SK1365-2003A 2001-05-09 2002-05-09 Potenciácia terapeutického účinku mastných kyselín SK13652003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0111282.0A GB0111282D0 (en)	2001-05-09	2001-05-09	Potentiation of therapeutic effects of fatty acids
PCT/GB2002/002145 WO2002089787A1 (en)	2001-05-09	2002-05-09	Potentiation of therapeutic effects of fatty acids

Publications (1)

Publication Number	Publication Date
SK13652003A3 true SK13652003A3 (sk)	2004-07-07

Family

ID=9914264

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1365-2003A SK13652003A3 (sk)	2001-05-09	2002-05-09	Potenciácia terapeutického účinku mastných kyselín

Country Status (26)

Country	Link
US (2)	US20020169209A1 (cs)
EP (1)	EP1392276B1 (cs)
JP (1)	JP4415243B2 (cs)
KR (1)	KR20030096355A (cs)
CN (1)	CN1638753A (cs)
AT (1)	ATE349207T1 (cs)
AU (1)	AU2002255164B2 (cs)
BR (1)	BR0209484A (cs)
CA (1)	CA2446363A1 (cs)
CZ (1)	CZ20032978A3 (cs)
DE (1)	DE60217103T2 (cs)
DK (1)	DK1392276T3 (cs)
EE (1)	EE200300549A (cs)
ES (1)	ES2279864T3 (cs)
GB (1)	GB0111282D0 (cs)
HU (1)	HUP0400010A2 (cs)
IL (1)	IL158678A (cs)
IS (1)	IS7004A (cs)
MX (1)	MXPA03010185A (cs)
NO (1)	NO20034920D0 (cs)
PL (1)	PL367508A1 (cs)
RU (1)	RU2003133449A (cs)
SK (1)	SK13652003A3 (cs)
UA (1)	UA79744C2 (cs)
WO (1)	WO2002089787A1 (cs)
ZA (1)	ZA200308417B (cs)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE10129320A1 (de)	2001-06-19	2003-04-10	Norbert Mueller	Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
JP2003048831A (ja)	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) *	2001-11-14	2003-05-20	Nutricia Nv	Preparaat voor het verbeteren van receptorwerking.
ITMI20020731A1 (it) *	2002-04-08	2003-10-08	Ibsa Inst Biochimique Sa	Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
WO2004028470A2 (en)	2002-09-27	2004-04-08	Martek Biosciences Corporation	Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
US8617617B2 (en) *	2002-12-10	2013-12-31	Everett Laboratories, Inc.	Methods and kits for co-administration of nutritional supplements
GB0301701D0 (en) *	2003-01-24	2003-02-26	Ensay Ltd	Psoriasis and Eicosapentaenoic acid
US20050032892A1 (en) *	2003-08-07	2005-02-10	The Procter & Gamble Company	Compositions, kits, and methods for treating gastrointestinal conditions
EP1683519A4 (en) *	2003-11-14	2009-04-01	Mochida Pharm Co Ltd	PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS
KR20060123329A (ko) *	2003-12-16	2006-12-01	오노 야꾸힝 고교 가부시키가이샤	월경 곤란증의 예방 및/또는 치료제
ES2247939B1 (es) *	2004-08-19	2007-04-01	Fernando Jose Garcia Fructuoso	Suplemento alimenticio basado en la utilizacion de acidos grasos omega-3 (dha-epa) para el tratamiento del sindrome de fatiga cronica.
JP4993852B2 (ja) *	2004-09-17	2012-08-08	サントリーホールディングス株式会社	ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
EP1833313A2 (en) *	2004-10-15	2007-09-19	Corporation Limited Photonz	Compositions containing high omega-3 and low saturated fatty acid levels
GB0428384D0 (en) *	2004-12-24	2005-02-02	Sla Pharma Ag	Eicosapentaenoic acid
NZ556163A (en) *	2005-01-10	2011-11-25	Univ California	Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors
US8324276B2 (en)	2005-01-24	2012-12-04	Pronova Biopharma Norge As	Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP3581178B1 (en) *	2005-02-14	2023-08-30	Suntory Holdings Limited	Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient
AU2006251562B2 (en)	2005-05-23	2012-03-22	Massachusetts Institute Of Technology	Compositions containing PUFA and methods of use thereof
RU2436571C2 (ru) *	2005-05-23	2011-12-20	Массачусетс Инститьют Оф Текнолоджи	Композиции, содержащие полиненасыщенные жирные кислоты (пнжк), и способы их применения
JP5967855B2 (ja)	2005-06-30	2016-08-10	サントリーホールディングス株式会社	日中活動量の低下および／又はうつ症状の改善作用を有する組成物
KR101465715B1 (ko) *	2005-07-08	2014-11-27	모치다 세이야쿠 가부시키가이샤	심혈관 이벤트 발병 예방용 조성물
US20070042008A1 (en) *	2005-08-18	2007-02-22	Bodybio, Inc.	Compositions containing phosphatidylcholine and essential fatty acids
US20070166411A1 (en) *	2005-12-16	2007-07-19	Bristol-Myers Squibb Company	Nutritional supplement containing long-chain polyunsaturated fatty acids
KR100697352B1 (ko) *	2006-01-03	2007-03-20	신승종	층간 소음 저감 구조체
EP2526937A1 (en) *	2006-02-07	2012-11-28	Mochida Pharmaceutical Co., Ltd.	Composition for prevention of recurrence of stroke
PL2189155T3 (pl) *	2006-04-12	2016-07-29	Unilever Nv	Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
EP2004161B8 (en) *	2006-04-12	2013-04-17	Unilever PLC	Oral composition comprising dha and genistein for enhancing skin properties
ES2391305T3 (es) *	2006-04-12	2012-11-23	Unilever N.V.	Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
KR100787765B1 (ko)	2006-11-07	2007-12-24	고려대학교 산학협력단	팔미트산을 포함하는 알츠하이머병의 예방 또는 치료용조성물
WO2008081989A1 (ja)	2006-12-28	2008-07-10	Suntory Holdings Limited	神経再生剤
CA2672513C (en)	2007-02-15	2010-05-25	Centre De Recherche Sur Les Biotechnologies Marines	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en)	2007-02-15	2014-08-26	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
EP2136844B1 (en)	2007-03-20	2018-10-31	SCF Pharma Inc.	Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
CA2639412A1 (en) *	2007-09-11	2009-03-11	Universite Laval	Prostaglandin e2 modulation and uses thereof
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2217075A4 (en)	2007-11-02	2012-01-25	Massachusetts Inst Technology	URIDINE FOOD ADDITIONAL AGREEMENT PROCESS AND USE THEREOF
US20090197955A1 (en) *	2008-01-31	2009-08-06	Monsanto Company	Methods of improving dha deposition and related function and/or development
EP4137128A1 (en)	2008-09-02	2023-02-22	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
ES2768091T3 (es)	2009-02-10	2020-06-19	Amarin Pharmaceuticals Ie Ltd	Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
NZ720946A (en)	2009-04-29	2017-09-29	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX350088B (es)	2009-04-29	2017-08-25	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011109681A1 (en) *	2010-03-05	2011-09-09	Catabasis Pharmaceuticals, Inc.	Fatty acid cox inhibitor derivatives and their uses
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en)	2010-11-29	2017-03-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2540292A1 (en) *	2011-06-28	2013-01-02	Nestec S.A.	DHA and EPA in the reduction of oxidative stress
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
WO2013072767A1 (en)	2011-11-18	2013-05-23	Pronova Biopharma Norge As	Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
ES2891473T3 (es)	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CA3067012C (en)	2012-06-29	2021-10-05	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9629820B2 (en)	2012-12-24	2017-04-25	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en)	2012-12-24	2018-11-13	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9447020B2 (en)	2013-10-31	2016-09-20	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016133788A1 (en)	2015-02-20	2016-08-25	The Regents Of The University Of California	Methods of inhibiting pain
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10639313B2 (en)	2017-09-01	2020-05-05	Ndsu Research Foundation	Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
CN111971041A (zh)	2018-02-07	2020-11-20	Scf制药股份有限公司	多不饱和脂肪酸单甘油酯、组合物、方法及其用途
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN112384212A (zh)	2018-05-03	2021-02-19	Scf制药股份有限公司	多不饱和脂肪酸单甘油酯、其组合物、方法和用途
MA51766A (fr)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US12226390B2 (en)	2019-07-21	2025-02-18	Scf Pharma Inc.	Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444755A (en) *	1978-01-23	1984-04-24	Efamol Limited	Treatment for skin disorders
US4273763A (en) *	1978-01-23	1981-06-16	Efamol Limited	Pharmaceutical and dietary compositions
GB8302708D0 (en) *	1983-02-01	1983-03-02	Efamol Ltd	Pharmaceutical and dietary composition
GB8507058D0 (en) *	1985-03-19	1985-04-24	Efamol Ltd	Pharmaceutical & dietary compositions
GB8524275D0 (en) *	1985-10-02	1985-11-06	Efamol Ltd	Pharmaceutical & dietary compositions
US5225441A (en) *	1987-06-18	1993-07-06	Block Drug Company, Inc.	Treatment of periodontal disease
US5198468A (en) *	1987-06-24	1993-03-30	Efamol Holdings Plc	Essential fatty acid composition
US5457130A (en) *	1989-03-20	1995-10-10	Cancer Research Campaign Technology Limited	Eicosapentaenoic acid used to treat cachexia
US5922345A (en) *	1990-12-07	1999-07-13	Scotia Holdings Plc	Nutrition
US5409955A (en) *	1993-05-13	1995-04-25	Bockow; Barry I.	Compositions and methods for inhibiting uterine contractility
US5411988A (en) *	1993-10-27	1995-05-02	Bockow; Barry I.	Compositions and methods for inhibiting inflammation and adhesion formation
GB9403855D0 (en) *	1994-03-01	1994-04-20	Scotia Holdings Plc	Fatty acid derivatives
GB9403857D0 (en) *	1994-03-01	1994-04-20	Scotia Holdings Plc	Fatty acid derivatives
US5709855A (en) *	1995-09-22	1998-01-20	Bockow; Barry I.	Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5840715A (en) *	1995-12-11	1998-11-24	Inholtra Investment Holdings & Trading, N.V.	Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US5912006A (en) *	1996-08-28	1999-06-15	Eboc, Inc.	Compositions and methods for alleviating discomforting menstrual pain
EP1762557B1 (en) *	2000-02-16	2011-04-06	The Brigham And Women's Hospital, Inc.	Aspirin-triggered lipid mediators

2001
- 2001-05-09 GB GBGB0111282.0A patent/GB0111282D0/en not_active Ceased
2002
- 2002-04-30 US US10/134,501 patent/US20020169209A1/en not_active Abandoned
- 2002-05-09 EE EEP200300549A patent/EE200300549A/xx unknown
- 2002-05-09 DE DE60217103T patent/DE60217103T2/de not_active Expired - Fee Related
- 2002-05-09 AT AT02724472T patent/ATE349207T1/de not_active IP Right Cessation
- 2002-05-09 KR KR10-2003-7014417A patent/KR20030096355A/ko not_active Withdrawn
- 2002-05-09 CZ CZ20032978A patent/CZ20032978A3/cs unknown
- 2002-05-09 MX MXPA03010185A patent/MXPA03010185A/es active IP Right Grant
- 2002-05-09 JP JP2002586922A patent/JP4415243B2/ja not_active Expired - Fee Related
- 2002-05-09 HU HU0400010A patent/HUP0400010A2/hu unknown
- 2002-05-09 EP EP02724472A patent/EP1392276B1/en not_active Expired - Lifetime
- 2002-05-09 IL IL158678A patent/IL158678A/en not_active IP Right Cessation
- 2002-05-09 PL PL02367508A patent/PL367508A1/xx not_active Application Discontinuation
- 2002-05-09 CN CNA028125800A patent/CN1638753A/zh active Pending
- 2002-05-09 SK SK1365-2003A patent/SK13652003A3/sk not_active Application Discontinuation
- 2002-05-09 BR BR0209484-3A patent/BR0209484A/pt not_active Application Discontinuation
- 2002-05-09 WO PCT/GB2002/002145 patent/WO2002089787A1/en not_active Ceased
- 2002-05-09 ES ES02724472T patent/ES2279864T3/es not_active Expired - Lifetime
- 2002-05-09 CA CA002446363A patent/CA2446363A1/en not_active Abandoned
- 2002-05-09 RU RU2003133449/15A patent/RU2003133449A/ru not_active Application Discontinuation
- 2002-05-09 DK DK02724472T patent/DK1392276T3/da active
- 2002-05-09 AU AU2002255164A patent/AU2002255164B2/en not_active Expired - Fee Related
- 2002-09-05 UA UA2003119997A patent/UA79744C2/uk unknown
2003
- 2003-10-29 ZA ZA200308417A patent/ZA200308417B/en unknown
- 2003-10-30 IS IS7004A patent/IS7004A/is unknown
- 2003-11-04 NO NO20034920A patent/NO20034920D0/no not_active Application Discontinuation
2005
- 2005-05-13 US US11/128,401 patent/US20050209329A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK1392276T3 (da)	2007-05-07
US20020169209A1 (en)	2002-11-14
WO2002089787A1 (en)	2002-11-14
US20050209329A1 (en)	2005-09-22
EP1392276A1 (en)	2004-03-03
NO20034920D0 (no)	2003-11-04
HUP0400010A2 (hu)	2004-04-28
ZA200308417B (en)	2004-05-24
DE60217103T2 (de)	2007-08-16
IL158678A0 (en)	2004-05-12
CA2446363A1 (en)	2002-11-14
EE200300549A (et)	2004-02-16
ES2279864T3 (es)	2007-09-01
CZ20032978A3 (cs)	2004-09-15
UA79744C2 (en)	2007-07-25
BR0209484A (pt)	2004-07-06
AU2002255164B2 (en)	2008-09-11
KR20030096355A (ko)	2003-12-24
IS7004A (is)	2003-10-30
CN1638753A (zh)	2005-07-13
JP2004537514A (ja)	2004-12-16
ATE349207T1 (de)	2007-01-15
RU2003133449A (ru)	2005-01-20
DE60217103D1 (de)	2007-02-08
EP1392276B1 (en)	2006-12-27
MXPA03010185A (es)	2004-03-16
PL367508A1 (en)	2005-02-21
GB0111282D0 (en)	2001-06-27
HK1059386A1 (en)	2004-07-02
IL158678A (en)	2008-06-05
JP4415243B2 (ja)	2010-02-17

Legal Events

Date	Code	Title	Description
2010-08-09	FC9A	Refused patent application

Publication	Publication Date	Title
EP1392276B1 (en)	2006-12-27	Potentiation of therapeutic effects of polyunsaturated fatty acids
AU2002255164A1 (en)	2003-05-01	Potentiation of therapeutic effects of fatty acids
CN100469363C (zh)	2009-03-18	脂肪酸的治疗组合物
US9763906B2 (en)	2017-09-19	Use of derivatives of polyunsaturated fatty acids as medicaments
SK14502003A3 (en)	2004-10-05	Coenzyme Q and eicosapentaenoic acid
AU2001274276A1 (en)	2002-04-11	Therapeutic combinations of fatty acids
JP2014506891A (ja)	2014-03-20	心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
HK1059386B (en)	2007-05-11	Potentiation of therapeutic effects of polyunsaturated fatty acids